PT1548032E - Péptidos kdr e vacinas que os contêm - Google Patents

Péptidos kdr e vacinas que os contêm Download PDF

Info

Publication number: PT1548032E
Authority: PT; Portugal
Prior art keywords: peptides; vaccines; amino acid; contain; seq
Prior art date: 2002-09-12

Application number

PT03795432T

Other languages

English (en)

Inventor

Hideaki Tahara

Satoshi Wada

Takuya Tsunoda

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-12

Filing date

2003-09-12

Publication date

2009-08-13

2003-09-12 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2009-08-13 Publication of PT1548032E publication Critical patent/PT1548032E/pt

Links

229960005486 vaccine Drugs 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
125000003275 alpha amino acid group Chemical group 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4208—Vascular endothelial growth factor receptors [VEGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Zoology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)

PT03795432T 2002-09-12 2003-09-12 Péptidos kdr e vacinas que os contêm PT1548032E (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002267285		2002-09-12
JP2003062003		2003-03-07
JP2003167042		2003-06-11

Publications (1)

Publication Number	Publication Date
PT1548032E true PT1548032E (pt)	2009-08-13

Family

ID=31998762

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT03795432T PT1548032E (pt)	2002-09-12	2003-09-12	Péptidos kdr e vacinas que os contêm
PT08018875T PT2014678E (pt)	2002-09-12	2003-09-12	Péptidos kdr e vacinas que os contêm

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT08018875T PT2014678E (pt)	2002-09-12	2003-09-12	Péptidos kdr e vacinas que os contêm

Country Status (13)

Country	Link
US (5)	US7514084B2 (pt)
EP (11)	EP1548032B9 (pt)
JP (3)	JP3971769B2 (pt)
CN (5)	CN100352843C (pt)
AT (2)	ATE531729T1 (pt)
AU (1)	AU2003264419A1 (pt)
CY (2)	CY1109463T1 (pt)
DE (1)	DE60327786D1 (pt)
DK (6)	DK2267022T3 (pt)
ES (2)	ES2327040T3 (pt)
PT (2)	PT1548032E (pt)
SI (2)	SI2014678T1 (pt)
WO (1)	WO2004024766A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1548032B9 (en)	2002-09-12	2009-10-28	Oncotherapy Science, Inc.	Kdr peptides and vaccines comprising the same
US9090673B2 (en)	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP4628208B2 (ja) *	2004-08-10	2011-02-09	オンコセラピー・サイエンス株式会社	Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
ES2459492T3 (es)	2005-02-25	2014-05-09	Oncotherapy Science, Inc.	Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
PT1855707E (pt)	2005-02-28	2012-05-25	Oncotherapy Science Inc	Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
US20060234941A1 (en) *	2005-04-15	2006-10-19	The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
WO2007013480A2 (en)	2005-07-29	2007-02-01	Oncotherapy Science, Inc.	Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
ES2804472T3 (es)	2005-12-13	2021-02-08	Harvard College	Estructuras para trasplante celular
DK2059256T3 (en)	2006-08-11	2016-12-05	Life Sciences Res Partners Vzw	Immunogenic peptides AND USE THEREOF FOR THE IMMUNE DISORDERS
TWI441648B (zh) *	2007-01-03	2014-06-21	Oncotherapy Science Inc	Ｆｏｘｐ３胜肽疫苗
CA2678432A1 (en) *	2007-02-16	2008-08-21	Oncotherapy Science, Inc.	Vaccine therapy for choroidal neovascularization
TWI434853B (zh) *	2007-04-11	2014-04-21	Oncotherapy Science Inc	腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200908998A (en) *	2007-06-27	2009-03-01	Oncotherapy Science Inc	Compositions and methods of treating cancer
DK2186889T3 (en) *	2007-08-20	2015-06-08	Oncotherapy Science Inc	CDCA1 PEPTID AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS
SG183717A1 (en)	2007-08-20	2012-09-27	Oncotherapy Science Inc	Foxm1 peptide and medicinal agent comprising the same
TWI436775B (zh) *	2007-08-24	2014-05-11	Oncotherapy Science Inc	以抗原胜肽合併化療藥劑治療胰臟癌
TW200932260A (en) *	2007-11-28	2009-08-01	Oncotherapy Science Inc	STAT3 epitope peptides
EP2254602B1 (en)	2008-02-13	2018-11-21	President and Fellows of Harvard College	Continuous cell programming devices
AU2009214042B2 (en)	2008-02-14	2014-02-13	Katholieke Universiteit Leuven	Immunotherapy targeting intracellular pathogens
AU2009214041A1 (en)	2008-02-14	2009-08-20	Katholieke Universiteit Leuven	CD4+ T-cells with cytolytic properties
AU2009214038B2 (en)	2008-02-14	2013-08-22	Katholieke Universiteit Leuven	Elimination of immune responses to viral vectors
AU2009214039B2 (en)	2008-02-14	2013-09-19	Katholieke Universiteit Leuven	Immunogenic control of tumours and tumour cells
TW201000119A (en) *	2008-06-10	2010-01-01	Oncotherapy Science Inc	MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh)	2008-06-19	2016-03-21	腫瘤療法科學股份有限公司	Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2898900B1 (en)	2008-09-19	2017-11-15	Nektar Therapeutics	Polymer conjugates of ziconotide
RU2532105C2 (ru)	2008-10-22	2014-10-27	Онкотерапи Сайенс, Инк.	Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
TWI539160B (zh) *	2008-12-05	2016-06-21	腫瘤療法科學股份有限公司	Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201032820A (en) *	2008-12-16	2010-09-16	Oncotherapy Science Inc	ELOVL7 epitope peptides and vaccines containing the same
EP2382314A4 (en) *	2008-12-24	2013-03-06	Oncotherapy Science Inc	C1ORF59 PEPTIDES AND VACCINES COMPRISING THEM
CN102348796B (zh)	2009-01-08	2015-05-13	株式会社癌免疫研究所	新型癌抗原eEF2
KR20110134446A (ko) *	2009-03-04	2011-12-14	온코세라피 사이언스 가부시키가이샤	Ｖａｎｇｌ１ 펩티드 및 이를 포함한 백신
HUE030856T2 (en)	2009-03-18	2017-06-28	Oncotherapy Science Inc	NEIL3 peptides and vaccines containing them
TW201100090A (en) *	2009-04-01	2011-01-01	Oncotherapy Science Inc	C6orf167 peptides and vaccines containing the same
TWI507204B (zh) *	2009-05-26	2015-11-11	Oncotherapy Science Inc	Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201109029A (en) *	2009-06-11	2011-03-16	Oncotherapy Science Inc	Vaccine therapy for choroidal neovascularization
CA2768552A1 (en) *	2009-07-31	2011-02-03	President And Fellows Of Harvard College	Programming of cells for tolerogenic therapies
TW201200525A (en) *	2009-12-04	2012-01-01	Oncotherapy Science Inc	MYBL2 peptides and vaccines containing the same
TW201136604A (en)	2009-12-14	2011-11-01	Oncotherapy Science Inc	TMEM22 peptides and vaccines including the same
CN102115492B (zh) *	2010-01-05	2013-03-06	中国农业科学院北京畜牧兽医研究所	血管内皮生长因子受体部分多肽及其应用
JP5838482B2 (ja)	2010-03-11	2016-01-06	オンコセラピー・サイエンス株式会社	Ｈｊｕｒｐペプチドおよびそれを含むワクチン
TW201134480A (en) *	2010-04-08	2011-10-16	Oncotherapy Science Inc	CLUAP1 peptides and vaccines including the same
JP2013523084A (ja) *	2010-04-09	2013-06-17	オンコセラピー・サイエンス株式会社	Ｃｄｃａ５ペプチドおよびそれを含むワクチン
WO2012032763A1 (en) *	2010-09-07	2012-03-15	Oncotherapy Science, Inc.	Vangl1 peptides and vaccines including the same
WO2012048165A2 (en)	2010-10-06	2012-04-12	President And Fellows Of Harvard College	Injectable, pore-forming hydrogels for materials-based cell therapies
CN103261218B (zh)	2010-11-25	2020-08-14	Imnate责任有限公司	免疫原性肽在预防和/或治疗疾病中的应用
UA110119C2 (xx) *	2010-12-02	2015-11-25		Пептиди tomm34 та вакцини, що їх містять
US9675561B2 (en)	2011-04-28	2017-06-13	President And Fellows Of Harvard College	Injectable cryogel vaccine devices and methods of use thereof
GB201201511D0 (en)	2012-01-30	2012-03-14	Univ Leuven Kath	Modified epitopes for boosting CD4+ T-cell responses
KR20140138900A (ko)	2012-03-09	2014-12-04	온코세라피 사이언스 가부시키가이샤	펩티드를 포함한 의약 조성물
CN104244929B (zh)	2012-04-16	2017-04-05	哈佛学院董事会	用于调节免疫反应的介孔二氧化硅组合物
US9416189B2 (en)	2012-05-11	2016-08-16	Microbial Chemistry Research Foundation	Anti-CXADR antibody
EP2872532A4 (en)	2012-07-10	2016-04-13	Oncotherapy Science Inc	CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
JP2016502499A (ja) *	2012-12-04	2016-01-28	オンコセラピー・サイエンス株式会社	Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
WO2014123227A1 (ja)	2013-02-08	2014-08-14	株式会社医学生物学研究所	ヒトｎｒｇ１タンパク質に対する抗体
GB201309469D0 (en)	2013-05-28	2013-07-10	Imcyse Sa	Detection of CD4+ T lymphocytes
JP2017042047A (ja) *	2013-12-06	2017-03-02	オンコセラピー・サイエンス株式会社	Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
EP3137105A4 (en)	2014-04-30	2017-12-27	President and Fellows of Harvard College	Combination vaccine devices and methods of killing cancer cells
GB201418433D0 (en)	2014-10-17	2014-12-03	Imcyse Sa	Novel immunogenic peptides
US11786457B2 (en)	2015-01-30	2023-10-17	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
WO2016129335A1 (ja) *	2015-02-09	2016-08-18	株式会社ライフアートビレッジ	免疫細胞療法のためのペプチドスクリーニング方法
WO2016164705A1 (en)	2015-04-10	2016-10-13	Omar Abdel-Rahman Ali	Immune cell trapping devices and methods for making and using the same
US10729791B2 (en)	2015-05-18	2020-08-04	Imcyse Sa	Animal models for evaluating pharmaceutical compounds
US11787849B2 (en)	2015-09-25	2023-10-17	Imcyse Sa	Methods and compounds for eliminating immune responses to therapeutic agents
CN105200010B (zh) *	2015-10-15	2019-02-12	首都医科大学附属北京佑安医院	艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
JP7138864B2 (ja)	2016-02-06	2022-09-20	プレジデントアンドフェローズオブハーバードカレッジ	免疫を再構成するための造血ニッチの再現
SG11201808710UA (en)	2016-04-19	2018-11-29	Imcyse Sa	Novel immunogenic cd1d binding peptides
US11555177B2 (en)	2016-07-13	2023-01-17	President And Fellows Of Harvard College	Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CA3032505A1 (en)	2016-08-02	2018-02-08	President And Fellows Of Harvard College	Biomaterials for modulating immune responses
JP7168228B2 (ja) *	2017-05-19	2022-11-09	慶應義塾	脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
TW202023581A (zh)	2018-08-02	2020-07-01	日商腫瘤療法科學股份有限公司	來自cdca1的胜肽及含有此的疫苗
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN111363026B (zh) *	2020-03-31	2022-03-25	浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院）	一种增强抗原多肽亲和力和稳定性的方法
KR102711471B1 (ko) *	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5861301A (en) *	1992-02-20	1999-01-19	American Cayanamid Company	Recombinant kinase insert domain containing receptor and gene encoding same
US6222012B1 (en) *	1992-08-31	2001-04-24	Ludwig Institute For Cancer Research	Isolated nonapeptides presented by HLA molecules, and uses thereof
CN1701814A (zh) *	1992-11-13	2005-11-30	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k－1
ATE281469T1 (de) *	1993-03-25	2004-11-15	Merck & Co Inc	Inhibitor des wachstumsfaktors für gefäss- endothelzellen
AU6632496A (en) *	1995-08-03	1997-03-05	Rijksuniversiteit Te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) *	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) *	1996-07-16	2000-06-27	Mixson; A. James	Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5942428A (en) *	1996-08-21	1999-08-24	Sugen, Inc.	Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
DE19638745C2 (de) *	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6348333B1 (en) *	1997-01-17	2002-02-19	Toa Gosei Co., Ltd.	VEGF-binding KDR polypeptide
DE69838334T2 (de) *	1997-06-18	2008-06-12	Merck & Co., Inc. (A New Jersey Corp.)	Kdr, ein menschlicher tyrosin kinase rezeptor
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6555652B1 (en) *	1997-12-05	2003-04-29	Kyogo Itoh	Tumor antigen peptide derivatives
WO1999040118A1 (en)	1998-02-04	1999-08-12	Kyowa Hakko Kogyo Co., Ltd.	Antibodies against human vegf receptor kdr
GB9804121D0 (en) *	1998-02-26	1998-04-22	Cancer Res Campaign Tech	Anti-angiogenic vaccines: materials and methods relating thereto
EP1086705A4 (en) *	1998-05-20	2002-02-06	Kyowa Hakko Kogyo Kk	INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
ATE375362T1 (de)	1998-06-25	2007-10-15	Kyogo Itoh	Von cyclophilin b abstammende tumorantigen- peptide
AU6600400A (en) *	1999-08-13	2001-03-13	Crucell Holland B.V.	Methods and means for inhibiting angiogenesis
US7264810B2 (en) *	2001-01-19	2007-09-04	Cytos Biotechnology Ag	Molecular antigen array
JP2002267285A (ja)	2001-03-12	2002-09-18	Denso Corp	冷房冷蔵装置
JP4068371B2 (ja)	2001-06-13	2008-03-26	株式会社トプコン	手術用顕微鏡
JP3640084B2 (ja)	2001-11-30	2005-04-20	日本電気株式会社	測位機能を搭載した携帯電話端末
CU23178A1 (es)	2002-04-15	2006-09-22	Ct Ingenieria Genetica Biotech	INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
EP1548032B9 (en) *	2002-09-12	2009-10-28	Oncotherapy Science, Inc.	Kdr peptides and vaccines comprising the same
ES2428354T3 (es)	2002-09-18	2013-11-07	Trustees Of The University Of Pennsylvania	Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
PT1855707E (pt)	2005-02-28	2012-05-25	Oncotherapy Science Inc	Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
CA2678432A1 (en)	2007-02-16	2008-08-21	Oncotherapy Science, Inc.	Vaccine therapy for choroidal neovascularization
TWI436775B (zh)	2007-08-24	2014-05-11	Oncotherapy Science Inc	以抗原胜肽合併化療藥劑治療胰臟癌

2003
- 2003-09-12 EP EP03795432A patent/EP1548032B9/en not_active Expired - Lifetime
- 2003-09-12 CN CNB038250810A patent/CN100352843C/zh not_active Expired - Lifetime
- 2003-09-12 US US10/527,496 patent/US7514084B2/en not_active Expired - Fee Related
- 2003-09-12 EP EP10010176.5A patent/EP2270042B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010171A patent/EP2261247A3/en not_active Withdrawn
- 2003-09-12 EP EP10010175.7A patent/EP2267023B1/en not_active Expired - Lifetime
- 2003-09-12 SI SI200332101T patent/SI2014678T1/sl unknown
- 2003-09-12 EP EP10010172.4A patent/EP2261248B1/en not_active Expired - Lifetime
- 2003-09-12 JP JP2004571938A patent/JP3971769B2/ja not_active Expired - Lifetime
- 2003-09-12 PT PT03795432T patent/PT1548032E/pt unknown
- 2003-09-12 WO PCT/JP2003/011722 patent/WO2004024766A1/ja not_active Ceased
- 2003-09-12 AT AT08018875T patent/ATE531729T1/de active
- 2003-09-12 DK DK10010174.0T patent/DK2267022T3/en active
- 2003-09-12 CN CN201410214247.3A patent/CN103951745A/zh active Pending
- 2003-09-12 DK DK03795432T patent/DK1548032T3/da active
- 2003-09-12 AU AU2003264419A patent/AU2003264419A1/en not_active Abandoned
- 2003-09-12 EP EP08018897A patent/EP2014679B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN2007101802052A patent/CN101139392B/zh not_active Expired - Fee Related
- 2003-09-12 CN CN2007101802067A patent/CN101139393B/zh not_active Expired - Fee Related
- 2003-09-12 CN CN201210430723.6A patent/CN103073620B/zh not_active Expired - Fee Related
- 2003-09-12 DE DE60327786T patent/DE60327786D1/de not_active Expired - Lifetime
- 2003-09-12 EP EP10010170.8A patent/EP2270041B1/en not_active Expired - Lifetime
- 2003-09-12 ES ES03795432T patent/ES2327040T3/es not_active Expired - Lifetime
- 2003-09-12 DK DK10010169.0T patent/DK2267021T3/en active
- 2003-09-12 SI SI200331649T patent/SI1548032T1/sl unknown
- 2003-09-12 AT AT03795432T patent/ATE432291T1/de active
- 2003-09-12 EP EP08018875A patent/EP2014678B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010169.0A patent/EP2267021B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010174.0A patent/EP2267022B1/en not_active Expired - Lifetime
- 2003-09-12 PT PT08018875T patent/PT2014678E/pt unknown
- 2003-09-12 ES ES08018875T patent/ES2375299T3/es not_active Expired - Lifetime
- 2003-09-12 EP EP10010173.2A patent/EP2261249B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK10010175.7T patent/DK2267023T3/en active
- 2003-09-12 DK DK10010173.2T patent/DK2261249T3/en active
- 2003-09-12 DK DK08018875.8T patent/DK2014678T3/da active
2007
- 2007-03-08 JP JP2007058127A patent/JP4185143B2/ja not_active Expired - Fee Related
- 2007-05-08 JP JP2007123850A patent/JP4185147B2/ja not_active Expired - Fee Related
2009
- 2009-01-16 US US12/355,616 patent/US7695720B2/en not_active Expired - Lifetime
- 2009-08-12 CY CY20091100856T patent/CY1109463T1/el unknown
2010
- 2010-02-23 US US12/711,159 patent/US8206719B2/en not_active Expired - Fee Related
2012
- 2012-01-19 CY CY20121100072T patent/CY1113379T1/el unknown
- 2012-06-12 US US13/494,930 patent/US8574585B2/en not_active Expired - Fee Related
- 2012-06-12 US US13/494,933 patent/US8574586B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HK1151032A1 (en)	2012-01-20
EP2267021A2 (en)	2010-12-29
HK1124077A1 (en)	2009-07-03
EP2270041A2 (en)	2011-01-05
EP2267023B1 (en)	2015-02-11
JP2007277251A (ja)	2007-10-25
DK2014678T3 (da)	2012-02-06
CN101139393B (zh)	2010-11-24
JP4185147B2 (ja)	2008-11-26
EP2261249B1 (en)	2015-02-11
DK2267023T3 (en)	2015-02-23
DK2267021T3 (en)	2015-03-30
US8206719B2 (en)	2012-06-26
EP2014679A1 (en)	2009-01-14
EP2270041A3 (en)	2011-02-16
EP2014678A3 (en)	2009-03-25
CY1113379T1 (el)	2016-06-22
EP2267022A3 (en)	2011-02-16
JP3971769B2 (ja)	2007-09-05
US20060216301A1 (en)	2006-09-28
EP2261249A2 (en)	2010-12-15
ATE531729T1 (de)	2011-11-15
US20120328636A1 (en)	2012-12-27
CN1694901A (zh)	2005-11-09
EP1548032A4 (en)	2006-03-01
EP2270042B1 (en)	2015-01-14
CN101139393A (zh)	2008-03-12
US8574585B2 (en)	2013-11-05
AU2003264419A1 (en)	2004-04-30
EP1548032B1 (en)	2009-05-27
JP2007191485A (ja)	2007-08-02
US20130028923A1 (en)	2013-01-31
SI2014678T1 (sl)	2012-03-30
JP4185143B2 (ja)	2008-11-26
US20090252752A1 (en)	2009-10-08
JPWO2004024766A1 (ja)	2006-01-26
EP2261248A3 (en)	2011-02-16
PT2014678E (pt)	2012-01-05
ES2327040T3 (es)	2009-10-23
WO2004024766A1 (ja)	2004-03-25
CN103951745A (zh)	2014-07-30
EP2261247A2 (en)	2010-12-15
US7695720B2 (en)	2010-04-13
DK1548032T3 (da)	2009-08-17
US7514084B2 (en)	2009-04-07
EP2261248A2 (en)	2010-12-15
CN100352843C (zh)	2007-12-05
EP1548032B9 (en)	2009-10-28
CY1109463T1 (el)	2014-08-13
CN103073620A (zh)	2013-05-01
CN103073620B (zh)	2014-12-10
EP2014678A2 (en)	2009-01-14
US20100215676A1 (en)	2010-08-26
HK1151039A1 (en)	2012-01-20
EP2267023A3 (en)	2011-02-16
CN101139392B (zh)	2012-12-26
ATE432291T1 (de)	2009-06-15
HK1151036A1 (en)	2012-01-20
EP2014679B1 (en)	2010-05-05
EP2261248B1 (en)	2015-02-18
HK1125659A1 (en)	2009-08-14
DK2261249T3 (en)	2015-02-16
EP2014678B1 (en)	2011-11-02
EP1548032A1 (en)	2005-06-29
DE60327786D1 (de)	2009-07-09
HK1151037A1 (en)	2012-01-20
US8574586B2 (en)	2013-11-05
ES2375299T3 (es)	2012-02-28
EP2267022A2 (en)	2010-12-29
EP2267022B1 (en)	2015-02-11
EP2270042A3 (en)	2011-02-16
EP2261249A3 (en)	2011-02-16
DK2267022T3 (en)	2015-02-23
CN101139392A (zh)	2008-03-12
EP2270041B1 (en)	2015-02-25
EP2267023A2 (en)	2010-12-29
HK1151038A1 (en)	2012-01-20
EP2267021A3 (en)	2011-02-16
SI1548032T1 (sl)	2009-10-31
EP2267021B1 (en)	2015-02-18
EP2261247A3 (en)	2011-02-16
EP2270042A2 (en)	2011-01-05

Publication	Publication Date	Title
PT1548032E (pt)	2009-08-13	Péptidos kdr e vacinas que os contêm
PT2121731E (pt)	2013-10-24	Vacinas peptídicas para cancros que expressam antigénios associados a tumores
ES2545457T3 (es)	2015-09-11	Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
BR0211200A (pt)	2004-09-28	Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DK1005540T3 (da)	2004-10-18	IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2006090810A3 (en)	2007-03-29	Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
DE60318391D1 (de)	2008-02-14	Bakteriophagen-lysin
CY1112867T1 (el)	2016-04-13	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
DE60230456D1 (de)	2009-01-29	Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE495247T1 (de)	2011-01-15	Chromoprotein und fluoroproteine
ATE455792T1 (de)	2010-02-15	Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
DE60336353D1 (de)	2011-04-21	Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
DK1095143T3 (da)	2009-01-05	Inhibitor til diagnosticering og behandling af patienter med hæmofili A
EP4047009A3 (en)	2022-11-16	Wdrpuh epitope peptides and vaccines containing the same
PT1537210E (pt)	2006-10-31	Inibicao de oliconucleotidos decoy de expressao cd-40
CY1114720T1 (el)	2016-10-05	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια